J. Craig Venter Institute

Opentrons Announces New Robotics Education Initiative Demonstrating Commitment to Laboratory Automation for Students

Retrieved on: 
Tuesday, March 12, 2024
University, Biotechnology, Primary, Secondary, Education, Technology, Health, Robotics, Other Science, Research, Science, Hardware, Automation, Virginia Tech, Assistant, Data analysis, MIT, Research design, University College London, Student, Ecosystem, Colorado State University, J. Craig Venter Institute, Carnegie Mellon University, Teaching, Associate professor

Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of Opentrons® for Education, an exclusive offering for educators to bring lab automation to the classroom.

Key Points: 
  • Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of Opentrons® for Education, an exclusive offering for educators to bring lab automation to the classroom.
  • Opentrons is building a first-of-its-kind ecosystem for teaching with automation, which includes education pricing and support, along with access to a community of educators already teaching with Opentrons.
  • Opentrons for Education is the key to unlocking a new era of hands-on, innovative learning in the realm of laboratory sciences.
  • in Automated Science Program, Computational Biology Department at Carnegie Mellon University, said, “This initiative underscores Opentrons' commitment to shaping the future of laboratory automation education for aspiring scientists.

BullFrog AI Issues Letter to Shareholders

Retrieved on: 
Friday, December 29, 2023
Partnership, Attention, Woman, Business, Drug development, Research, Colorectal cancer, Burn, Patent, Bullfrog, Artificial intelligence, Cancer, Glioblastoma, J. Craig Venter Institute, American Cancer Society, Obesity, Genomics, Machine learning, DSM-IV codes, Face, IPO, Solubility, Liver disease, United States patent law, Algorithm, Skin, Environment

GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to shareholders from its CEO Vin Singh.

Key Points: 
  • GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to shareholders from its CEO Vin Singh.
  • Looking back at 2023, it is evident that it has been an extraordinary year for BullFrog AI.
  • Amidst the frenzy and hype surrounding AI, our team has remained steadfast in our focus, diligently executing our plan with unwavering determination.
  • Given our float of 2.8 million shares and the high-value transactions in our sector, we believe the future looks incredibly bright for BullFrog AI, our partners, and most importantly, you - our valued shareholders.

PolyBio Research Foundation receives $15M for extended Long COVID research and clinical trials

Retrieved on: 
Wednesday, November 1, 2023
Principal, J. Craig Venter Institute, Laboratory, Cohen Center for Holocaust and Genocide Studies, Core, Harvard Medical School, Coronavirus, UCSF, Karolinska Institute, Johns Hopkins University, Assistant, SARS-CoV-2, Nature Immunology, Physician, Icahn School of Medicine at Mount Sinai, Atmosphere, Research, Virus, University of Pennsylvania, Multimedia, University of California, San Francisco, Aerosol, COVID, Vitalik Buterin, Consortium, Clinical trial, COVID-19, Mount Sinai, N95, University, HEPA, San Francisco, Alzheimer's disease, Patient, Infection, Pharmaceutical industry, Vaccine, Long COVID, Ethereum, Medicine

MEDFORD, Mass., Nov. 1, 2023 /PRNewswire/ -- PolyBio Research Foundation has announced a $15M gift from Kanro: a philanthropic fund to support scientific research established by Vitalik Buterin, co-founder of Ethereum. The funding will support a second phase of research and clinical trials via the LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly and openly study core biological drivers of Long COVID. This is Buterin's second $15M gift to the Consortium and will allow dozens of new projects to move forward.

Key Points: 
  • The funding will support a second phase of research and clinical trials via the LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly and openly study core biological drivers of Long COVID.
  • LCRC research thus far demonstrates that reservoirs of the virus can persist for months - or even years - in the tissue of Long COVID patients.
  • "Mechanisms underlying Long COVID are not a mystery," says Dr. Amy Proal PhD, PolyBio's Chief Scientific Officer.
  • "The persistence of SARS-CoV-2 in tissue is a major target for rapid research and clinical trials."

BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform

Retrieved on: 
Thursday, October 5, 2023
Algorithm, Partnership, American Cancer Society, Machine learning, JCVI, Anomaly, J. Craig Venter Institute, Data, The Cancer Genome Atlas, Cancer, Artificial intelligence, Bullfrog, Colorectal cancer, TCGA, Literature, Neoplasm, Woman, Genomics, Research, Skin, Vaccine

GAITHERSBURG, Md., Oct. 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that it has identified multiple potential therapeutic targets, including three novel targets, for colorectal cancer using the Company’s proprietary AI-driven platform, bfLEAP™. The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a world-leading genomics research and innovation institution. JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.

Key Points: 
  • The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a world-leading genomics research and innovation institution.
  • JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.
  • “TCGA has been extensively analyzed by scientists for more than a decade, yet in a matter of weeks, we were able to identify multiple new drug target candidates with previously undocumented potential in colorectal cancer from this same dataset,” stated Vin Singh, Chairman and CEO of BullFrog AI.
  • "These findings demonstrate the power and potential of our bfLEAP™ platform, which combines advanced AI algorithms with rich biological data to identify novel targets for a wide range of diseases.

Integral Group and Ross & Baruzzini Come Together Under New Brand, Introba, to Meet Increasing Global Demand for Sustainable, Resilient Engineering

Retrieved on: 
Tuesday, August 16, 2022
Professional Services, Electronic Design Automation, Sustainability, Technology, Environment, Construction & Property, Security, Green Technology, Engineering, Building Systems, Consulting, Manufacturing, Zero, Carbon, Multimedia, Georgia Tech, United Kingdom, CEO, World Green Building Council, National Nuclear Laboratory, Ross, J. Craig Venter Institute, Business Integration Group, Inc., MD Anderson Cancer Center, Leadership, Georgia Institute of Technology Institute for Robotics and Intelligent Machines, Integral, Environment, Government, Lululemon Athletica, Engineering, Education, Aviation, Hydes, World Trade Center, Health, Culture, Science, World, University, MEP, Solution, Consultant, Adoption, Online gambling, Renewable energy, Construction, Risk management, Technology

Integral Group, a global network of deep green engineers and consultants, and Ross & Baruzzini, a technology, consulting, and engineering firm, announced they are combining entities under a new brand name, Introba.

Key Points: 
  • Integral Group, a global network of deep green engineers and consultants, and Ross & Baruzzini, a technology, consulting, and engineering firm, announced they are combining entities under a new brand name, Introba.
  • Integral Group was a founding signatory of the World Green Building Council's Net Zero Carbon Commitment and Carbon Leadership Forum's MEP 2040 Challenge.
  • Ross & Baruzzini was incorporated by Donald Ross, Sc.D., P.E, and Joseph Baruzzini in 1962.
  • "Together, we now offer our clients more by combining our skills and resources," said Bill Overturf, president of Integral Group and Ross & Baruzzini.

VistaGen Appoints Reid Adler as Chief Legal Officer

Retrieved on: 
Monday, May 2, 2022
Legal, Mental Health, Research, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Transfer, Technology transfer, Board, Strategic planning, Board of directors, University, Brain, Nasdaq, University of Maryland, College Park, College Park, CNS, Company, Mixed anxiety–depressive disorder, NIH, Adler, Depression, Â, PH94B, Central nervous system disease, Patient, Neuron, Organization, FDA, Coalition for Epidemic Preparedness Innovations, Coalition, Therapy, Anxiety, National, Epidemic, Genomics, Vaccine, Hotel manager, Bachelor of Science in Human Biology, George Washington University, Social anxiety disorder, J. Craig Venter Institute, NIH Office of Technology Transfer, Technology, Research, Morrison & Foerster, Central nervous system, Management, Medicine, Pharmaceutical industry

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer.

Key Points: 
  • VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer.
  • Adler will oversee VistaGen's legal affairs and provide strategic guidance to its Executive Team and Board of Directors.
  • We are excited to welcome Reid to VistaGens Executive Team, said Shawn Singh, Chief Executive Officer .
  • It's a privilege to join the VistaGen leadership team after supporting the companys efforts as outside counsel, stated Reid Adler.

Diabetes Research Connection Announces 2022 Scientific Review Committee

Retrieved on: 
Monday, February 28, 2022
Diabetes, Science, Health, Research, Science, Patient, Investor, University, Child Care & Early Education Research Connections, SRC, Solution, Research, J. Craig Venter Institute, DRC, Pharmaceutical industry, Medical device, T1D

Diabetes Research Connection (DRC), a 501(c)(3) that funds research projects conducted by early-career scientists aimed at prevention, better care, treatment of related complications, and a cure for T1D, announces its Scientific Review Committee (SRC) for 2022.

Key Points: 
  • Diabetes Research Connection (DRC), a 501(c)(3) that funds research projects conducted by early-career scientists aimed at prevention, better care, treatment of related complications, and a cure for T1D, announces its Scientific Review Committee (SRC) for 2022.
  • The committee members volunteer their expertise and time to thoroughly vet T1D research funding applications DRC receives based on their scientific merit.
  • I hope to contribute my biological engineering perspectives, which may be non-standard in T1D research, to helping guide future research directions.
  • Diabetes Research Connection was established by five tireless proponents of diabetes research motivated to connect donors with early-career scientists and support novel, peer-reviewed studies on ways to prevent, treat and cure type 1 diabetes (T1D).

TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors

Retrieved on: 
Thursday, August 26, 2021
Ovarian cancer, Private Securities Litigation Reform Act, Foundation Medicine, Cancer, U.S. Securities and Exchange Commission, Biochemical pharmacology, PD-L1, GLOBE, Board of directors, The Institute, Research, Nasdaq, Director, Disease, Cholangiocarcinoma, Risk, Therapy, University at Buffalo, Cell, Genentech, Review, Clinical trial, Board, Translational Genomics Research Institute, Aall, Genomics, J. Craig Venter Institute, HLA, University of Mumbai, GlaxoSmithKline, NSCLC, Patient, Acute lymphoblastic leukemia, Cytokine, Â, Doctor of Philosophy, COVID-19, Annual report, Pharmacology, NHL, Lymphatic system, TCR, Pharmaceutical industry, Vaccine

Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine.

Key Points: 
  • Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine.
  • Once again, we are thrilled be adding to the board such a highly regarded scientist with expertise specific to the needs of the company.
  • Prior to joining Genentech, Dr. Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.

KGI Professor Larry Grill and Team Producing Low-Cost Vaccine for Developing Countries

Retrieved on: 
Thursday, August 12, 2021
Medicine, Human, Botswana Vaccine Institute Staff Union, Milk, Lumpy skin disease, COVID, Cancer vaccine targeting CD4+ T cells, Disease, Cattle, Death, Lists of countries and territories, COVID-19, Immune system, Keck Graduate Institute, Virus, Antibody, APC, Mouse, TMV, Plant, Plant virus, Tobacco mosaic virus, LSD, KGI, Student, Vaccine, Class II, Protein, Class, J. Craig Venter Institute, Pharmaceutical industry

To take advantage of this feature, Grill and his team changed the outside surface of the plant virus to resemble a real pathogen.

Key Points: 
  • To take advantage of this feature, Grill and his team changed the outside surface of the plant virus to resemble a real pathogen.
  • "Injectable pure material costs less than 15 cents a dose, so when you're talking about developing countries, that's pretty important," Grill said.
  • After fusing several LSD coat protein peptides to the TMV coat protein to create a vaccine, Grill and his team began vaccinating cattle.
  • Their goal is not to compete with the big pharma vaccine companies but rather to produce a low-cost vaccine for developing countries.

Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Genetics, Health, Oncology, Branches of biology, Biology, Genetics, Craig Venter, J. Craig Venter Institute, Celera Corporation, Genomics

VAHOCA Pte Ltd acted as a financial advisor to Bluestar Genomics.\nSeparately, the company announces the expansion of its Scientific Advisory Board, with the appointment of Drs.

Key Points: 
  • VAHOCA Pte Ltd acted as a financial advisor to Bluestar Genomics.\nSeparately, the company announces the expansion of its Scientific Advisory Board, with the appointment of Drs.
  • Felix Feng, professor of radiation oncology, urology, and medicine, University of California San Francisco, and Craig Venter, Ph.D., chairman and CEO of the J. Craig Venter Institute.
  • Their leading scientific and clinical expertise will help accelerate our development and commercialization efforts,\xe2\x80\x9d said Samuel Levy, Ph.D., chief executive, and chief scientific officer at Bluestar Genomics.
  • Founded based on the work of Dr. Stephen Quake, Bluestar Genomics combines novel epigenomic technologies with its innovative machine learning architecture to tackle the most urgent challenges such as cancer detection.